These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35948575)

  • 41. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 42. Multivariable stratification of PI-RADS version 2.1 categories for the risk of false-positive target biopsy: Impact on prostate biopsy decisions.
    Girometti R; Giannarini G; De Martino M; Caregnato E; Cereser L; Soligo M; Rozze D; Pizzolitto S; Isola M; Zuiani C
    Eur J Radiol; 2023 Aug; 165():110897. PubMed ID: 37300933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.
    Dai Z; Liu Y; Huangfu Z; Wang L; Liu Z
    Med Sci Monit; 2021 Aug; 27():e930234. PubMed ID: 34365459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
    Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
    AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
    [No Abstract]   [Full Text] [Related]  

  • 45. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.
    Boschheidgen M; Schimmöller L; Doerfler S; Al-Monajjed R; Morawitz J; Ziayee F; Mally D; Quentin M; Arsov C; Albers P; Antoch G; Ullrich T
    Sci Rep; 2022 Apr; 12(1):6746. PubMed ID: 35469056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A prospective study of cancer detection rates following early repeat imaging and biopsy of PI-RADS 4 and 5 regions of interest exhibiting no clinically significant prostate cancer on prior biopsy.
    Becher E; Wysock JS; Taneja SS; Huang WC; Lepor H
    Can Urol Assoc J; 2022 Dec; 16(12):418-422. PubMed ID: 36656702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Performance of Combined Magnetic Resonance Imaging/Ultrasound Fusion-guided and Systematic Biopsy of the Prostate in Biopsy-naïve Patients and Patients with Prior Biopsies.
    Preisser F; Theissen L; Wenzel M; Humke C; Bodelle B; Köllermann J; Kluth L; Banek S; Becker A; Roos F; Chun FK; Mandel P
    Eur Urol Focus; 2021 Jan; 7(1):39-46. PubMed ID: 31296485
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA ≥4 ng/mL: a systematic review and meta-analysis.
    Zhu K; Qin Z; Xue J; Miao C; Tian Y; Liu S; Zhu S; Gu Q; Hou C; Xu A; Yang J; Wang Z
    Transl Androl Urol; 2019 Dec; 8(6):741-753. PubMed ID: 32038971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR
    BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.
    Venderink W; van Luijtelaar A; Bomers JGR; van der Leest M; Hulsbergen-van de Kaa C; Barentsz JO; Sedelaar JPM; Fütterer JJ
    Eur Urol; 2018 Mar; 73(3):353-360. PubMed ID: 28258784
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: A prospective evaluation of the PLUM cohort.
    Patel HD; Koehne EL; Shea SM; Bhanji Y; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Gupta GN
    Cancer; 2022 Jan; 128(1):75-84. PubMed ID: 34427930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
    Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
    Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naïve men?
    Wang G; Yu G; Chen J; Yang G; Xu H; Chen Z; Wang G; Bai Z
    Clin Imaging; 2022 Aug; 88():80-86. PubMed ID: 34243992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic Accuracy and Value of Magnetic Resonance Imaging-Ultrasound Fusion Transperineal Targeted and Template Systematic Prostate Biopsy Based on Bi-parametric Magnetic Resonance Imaging.
    Noh TI; Tae JH; Kim HK; Shim JS; Kang SG; Sung DJ; Cheon J; Lee JG; Kang SH
    Cancer Res Treat; 2020 Jul; 52(3):714-721. PubMed ID: 32054151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI.
    Nguyen TA; Fourcade A; Zambon A; Saout K; Deruelle C; Joulin V; Tissot V; Doucet L; Rozet F; Fournier G; Valeri A
    Urol Oncol; 2023 Aug; 41(8):354.e11-354.e18. PubMed ID: 37391283
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can we omit systematic biopsies in patients undergoing MRI fusion-targeted prostate biopsies?
    Leow JJ; Koh SH; Chow MW; Loke W; Salada R; Hong SK; Yeow Y; Lee CH; Tan CH; Tan TW
    Asian J Androl; 2023; 25(1):43-49. PubMed ID: 35488666
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer.
    Venderink W; van der Leest M; van Luijtelaar A; van de Ven WJM; Fütterer JJ; Sedelaar JPM; Huisman HJ
    World J Urol; 2017 Dec; 35(12):1849-1855. PubMed ID: 28871396
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Initial experience of magnetic resonance imaging/ultrasonography fusion transperineal biopsy: Biopsy techniques and results for 75 patients.
    Tae JH; Shim JS; Jin HJ; Yoon SG; No TI; Kim JY; Kang SH; Cheon J; Kang SG
    Investig Clin Urol; 2018 Nov; 59(6):363-370. PubMed ID: 30402568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
    Wegelin O; Exterkate L; van der Leest M; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; Barentsz JO; Somford DM; van Melick HHE
    Eur Urol; 2019 Apr; 75(4):582-590. PubMed ID: 30522912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.